Back pain is the second leading cause of disability among American adults and is currently treated either with conservative therapy or interventional pain procedures.
PRP and Stem Cells in Chronic Low Back Pain May 2017Back pain is the second leading cause of disability among American adults and is currently treated either with conservative therapy or interventional pain procedures.
PRP and Stem Cells in Chronic Low Back Pain May 2017Osteoarthritis (OA) of the knee is a progressive disease involving the intra-articular (IA) tibiofemoral and patellofemoral cartilage1). Conservative treatment modalities are the first choice in younger and middle-aged populations with cartilage damage and OA of the knee.
PRP in Knee OA June 2017Meniscal cartilage tears are common and predispose to osteoarthritis (OA). Most occur in the avascular portion of the meniscus where current repair techniques usually fail. We described previously the use of undifferentiated autologous mesenchymal stem cells (MSCs) seeded onto a collagen scaffold (MSC/collagen-scaffold) to integrate meniscal tissues in vitro.
MSC's to Repair Meniscal Cartilage April 2017To compare two platelet-rich plasma kits with different platelet concentrations for treatment of knee osteoarthritis. [Subjects and Methods] Male and female patients with knee osteoarthritis who had confirmed diagnosis with X-ray and magnetic resonance imaging were included in this retrospective study
PRP in Early Stage Osteoarthritis June 2017Osteoarthritis (OA) is a degenerative disease characterized by the slow progressive destruction of articular cartilage accompanied by changes to synovium and subchondral bone, degeneration of ligaments and menisci and hypertrophy of the joint capsule.
PRP and SVF in Osteoparthritis June 2017Osteoarthritis (OA) is the most common joint disease and a major cause of disability. According to the National Health Interview Survey, more than 50 million adults have been diagnosed with OA in the United States in 2012.1
MSC's in Tx of Hip Osteoarthritis Mar 2017As the most common form of joint disorder, osteoarthritis (OA) imposes a tremendous burden on health care systems worldwide. Without effective cure, OA represents a unique opportunity for innovation in therapeutic development. In contrast to traditional treatments based on drugs, proteins, or antibodies, stem cells are poised to revolutionize medicine as they possess the capacity to replace and repair tissues and organs such as osteoarthritic joints.
MSC's in OA April 2017Osteoarthritis (OA) is a common degenerative joint disease, characterised by progressive cartilage breakdown, subchondral bone sclerosis and aberrant bone outgrowths (osteophytes). Traumatic joint lesions increase the risk of OA. Advances in the regenerative treatment of early cartilage lesions could help to prevent OA.
Stem Cell Therapeutics in Cartilage and OA repair Apr 2018